NEW YORK, Feb 9 ― Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported yesterday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfil delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a “few” months, the Times reported.
J&J currently has “millions of doses of our Covid-19 vaccine in inventory,” according to the J&J spokesman.
“We continue to fulfil our contractual obligations in relation to the Covax facility and the African Union,” the company spokesman said.
J&J has projected sales of US$3 billion (RM12.55 billion) to US$3.5 billion in 2022 for its Covid-19 vaccine, much less than the US$32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said. ― AFP
